Resverlogix Announces Voting Results From The 2017 Annual Meeting Of Shareholders

CALGARY, Alberta, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) announced today that, at its annual meeting of shareholders held on December 12, 2017, Resverlogix shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated October 30, 2017 (the “Information Circular”), which is available on SEDAR at www.sedar.com, and on the Resverlogix website at www.resverlogix.com.

1.  Fixing the Number of Directors and Election of Directors

By resolution passed by ballot vote, each of the six nominees proposed as a director were elected as directors of the Corporation to hold office until the next annual meeting of Shareholders or until their successors are elected or appointed. 

The voting results for each nominee is set out below:

	Votes For	Votes Withheld		Percent For	Percent Withheld
Donald J. McCaffrey	33,234,615	172,543	99.48			0.52
Norma Biln	33,299,805	107,353	99.68			0.32
Shawn Lu	33,187,705	219,453	99.34			0.66
Kelly McNeill	33,302,505	104,653	99.69			0.31
Dr. Eldon Smith	33,299,805	107,353	98.68			0.32
Kenneth Zuerblis	33,319,505	87,653	99.74			0.26

2.  Appointment of Auditors

By resolution passed by show of hands, KPMG LLP, Chartered Accountants, was appointed as auditor of the Corporation to hold office until the next annual general meeting of the Shareholders and to authorize the Board to fix the auditor’s remuneration.

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL), and is expected to be initiated in a Phase 2a kidney dialysis trial designed to evaluate biomarker changes and safety parameters in up to 30 patients with end-stage renal disease treated with hemodialysis.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

Follow us on Twitter:  https://mobile.twitter.com/resverlogix_rvx

For further information please contact:

Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
Or visit our website: www.resverlogix.com